Descubre y comparte nuestro conocimiento público

Se han encontrado 3 recursos

Resultados de búsqueda

Article 2018

Autor: Lorca, M. Morales-Verdejo, C. Vásquez-Velásquez, D. Andrades-Lagos, J. Campanini-Salinas, J. Soto-Delgado, J. Recabarren-Gajardo, G. Mella, J.

The wide tissue distribution of the adrenergic β3 receptor makes it a potential target for the treatment of multiple pathologies such as diabetes, obesity, depression, overactive bladder (OAB), and cancer. Currently, there is only one drug on the market, mirabegron, approved for the treatment of ...

Enlace original: http://repositorio.unab.cl/xmlui/handle/ria/8959

Repositorio Universidad Andrés Bello
Enlace permanente

Lorca, M. ,  Morales-Verdejo, C. ,  Vásquez-Velásquez, D. ,  Andrades-Lagos, J. ,  Campanini-Salinas, J. ,  Soto-Delgado, J. ,  Recabarren-Gajardo, G. ,  Mella, J. ,  [Structure-activity relationships based on 3D-QSAR CoMFA/CoMSIA and design of aryloxypropanol-amine agonists with selectivity for the human β3-adrenergic receptor and anti-obesity and anti-diabetic profiles] ,  Structure-activity relationships based on 3D-QSAR CoMFA/CoMSIA and design of aryloxypropanol-amine agonists with selectivity for the human β3-adrenergic receptor and anti-obesity and anti-diabetic profiles
Article 2017-03

Autor: Apablaza, G. Montoya, L. Morales-Verdejo, C. Mellado, M. Cuellar, M. Lagos, C.F. Soto-Delgado, J. Chung, H. Pessoa-Mahana, C.D. Mella, J.

The beta(3) adrenergic receptor is raising as an important drug target for the treatment of pathologies such as diabetes, obesity, depression, and cardiac diseases among others. Several attempts to obtain selective and high affinity ligands have been made. Currently, Mirabegron is the only availa...

Enlace original: http://repositorio.unab.cl/xmlui/handle/ria/4255

Repositorio Universidad Andrés Bello
Enlace permanente

Apablaza, G. ,  Montoya, L. ,  Morales-Verdejo, C. ,  Mellado, M. ,  Cuellar, M. ,  Lagos, C.F. ,  Soto-Delgado, J. ,  Chung, H. ,  Pessoa-Mahana, C.D. ,  Mella, J. ,  [2D-QSAR and 3D-QSAR/CoMSIA studies on a series of (R)-2-((2-(1H-Indol-2-yl)ethyl)amino)-1-phenylethan-1-ol with human β3-adrenergic activity] ,  2D-QSAR and 3D-QSAR/CoMSIA studies on a series of (R)-2-((2-(1H-Indol-2-yl)ethyl)amino)-1-phenylethan-1-ol with human β3-adrenergic activity
Article 2013

The application of ligand-based drug design methods such as quantitative structure-activity relationship (QSAR) is a mandatory issue in the design of luteinizing hormone-releasing hormone (LHRH) receptor antagonists because the lack of information on the molecular structure for this target protei...

Enlace original: http://dspace.utalca.cl/handle/1950/9437

Repositorio Universidad de Talca
Enlace permanente

Selecciona los documentos para visualizarlos

Nombre del archivo Ver recurso
Marcar todos
Limpiar todo